Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

Canada NewsWire June 17, 2021

Psilocybin Could Help Treat Nearly 264 Million with Depression

Press Releases June 10, 2021

MindMed Announces Chief Executive Officer Transition

Canada NewsWire June 9, 2021

NIH Director Touted Benefits of Psychedelics Including Psilocybin and MDMA

Press Releases May 28, 2021

MindMed announces shareholder Meeting Results

Canada NewsWire May 27, 2021

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

Canada NewsWire May 26, 2021

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

Canada NewsWire May 24, 2021

MindMed Announces the Approval of Mescaline Study

Canada NewsWire May 20, 2021

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Canada NewsWire May 18, 2021

The World May be Closer to Better Treatments for Parkinson's Disease

Press Releases May 17, 2021

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

PR Newswire May 17, 2021

MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

Canada NewsWire May 14, 2021

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

Canada NewsWire May 14, 2021

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Canada NewsWire May 13, 2021

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics

Canada NewsWire May 5, 2021

Psilocybin May Be Helpful for Those with Traumatic Brain Injury

Press Releases April 27, 2021

MindMed Begins Trading on Nasdaq

PR Newswire April 27, 2021

MindMed To Commence Trading on Nasdaq

Canada NewsWire April 23, 2021

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Canada NewsWire April 5, 2021

MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS

Canada NewsWire March 30, 2021